Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCND1 | P24385 | 18/20 | 0.54 |
| ▸ | CDK6 | Q00534 | 18/20 | 0.54 |
| ▸ | CCNE1 | P24864 | 18/20 | 0.54 |
| ▸ | CDK2 | P24941 | 18/20 | 0.54 |
| ▸ | CCNT1 | O60563 | 4/20 | 0.54 |
| ▸ | CDK9 | P50750 | 4/20 | 0.54 |
| ▸ | CDK4 | P11802 | 3/20 | 0.54 |
| ▸ | CCND3 | P30281 | 1/20 | 0.54 |
| ▸ | LCK | P06239 | 1/20 | 0.51 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4089878 | 0.92 | LCK (0.51) | CCND1CDK6CCNE1CDK2CCNT1 | |
| SCHEMBL4095478 | 0.90 | LCK (0.48) | CCND1CDK6CCNE1CDK2CCNT1 | |
| SCHEMBL4094501 | 0.89 | LCK (0.57) | CCND1CDK6CCNE1CDK2CCNT1 | |
| SCHEMBL4101334 | 0.89 | LCK (0.47) | CCND1CDK6CCNE1CDK2CCNT1 | |
| SCHEMBL4089655 | 0.89 | LCK (0.63) | LCKMAPK14 | |
| SCHEMBL4095825 | 0.86 | LCK (0.45) | CCND1CDK6CCNE1CDK2CCNT1 | |
| SCHEMBL4097349 | 0.86 | LCK (0.51) | CCND1CDK6CCNE1CDK2CCNT1 | |
| SCHEMBL4089113 | 0.85 | LCK (0.45) | CCND1CDK6CCNE1CDK2CCNT1 | |
| SCHEMBL4094757 | 0.85 | LCK (0.50) | CCND1CDK6CCNE1CDK2CCNT1 | |
| SCHEMBL4088976 | 0.85 | LCK (0.44) | CCND1CDK6CCNE1CDK2CCNT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | claimed |
| EP-1831215-A1 | PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-09-12 | — | — | EP | claimed |
| WO-2006056863-A1 | PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-01 | — | — | WO | claimed |
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2009-05-21 | — | — | US | disclosed |
| EP-1831215-A1 | PYRIDO[2,3-D]PYRIMIDINES AS ANTI-INFLAMATORY AGENTS | Ranbaxy Laboratories Limited (IN) | 2007-09-12 | — | — | EP | disclosed |
| WO-2006056863-A1 | PYRIDO’2, 3-D!PYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | RANBAXY LABORATORIES LIMITED (IN) | 2006-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090131430-A1 | PYRIDO'2,3-DIPYRIMIDINES AS ANTI-INFLAMMATORY AGENTS | TLR1, TPMT, NOD1 | CCND1 905/4885CDK6 204/4885CCNE1 1751/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.